Tumour localisation with a radioactively labelled reshaped human monoclonal antibody.
A genetically reshaped human IgG1 monoclonal antibody (Hu2PLAP) with anti-tumour specificity, was radiolabelled with Indium-111 by chelation with a new macrocyclic compound (DOTA) which allows the production of stable radioimmunoconjugates for in vivo application. This was used to image seven patients with malignant disease, of whom two had been previously exposed to mouse monoclonal antibodies and had developed human anti-mouse antibodies (HAMA). Successful tumour localisation was seen in the four patients with active disease and antigen positive tumours. No patient showed any antibody responses against Hu2PLAP, but three out of six patients tested showed an immune response against the macrocycle DOTA. Reshaped human monoclonal antibodies with anti-tumour specificity may facilitate repeated administrations of radioactive antibodies, thus allowing new possibilities, both in the diagnosis and treatment of cancer.
Imperial Cancer Research Fund Oncology Group, Department of Clinical Oncology, Royal Postgraduate Medical School, Hammersmith Hospital, London, UK.
V
V
Hird
M
M
Verhoeyen
R A
RA
Badley
D
D
Price
D
D
Snook
C
C
Kosmas
C
C
Gooden
A
A
Bamias
C
C
Meares
J P
JP
Lavender
D000328:Adult; D000368:Aged; D000917:Antibody Formation; D006801:Humans; D007205:Indium Radioisotopes; D008875:Middle Aged; D009369:Neoplasms / Q000000981:diagnostic imaging*; D016719:Radioimmunodetection
D007205:Indium Radioisotopes